Activation of central 5HT2A receptors reduces the craniofacial nociception of rats.
We assessed the contribution of central 5HT2A receptors to the craniofacial tissue nociception in naïve male rats. First, we tested whether activation of central 5HT2A receptors affected nociceptive neural activities recorded from superficial laminae of the trigeminal subnucleus caudalis (Vc)/upper cervical spinal cord junction (Vc/C2) region. Two types of units, such as deep-nociceptive or skin-wide dynamic range (WDR) units were identified from extracellular recordings. Topical administration of 5HT2A receptor agonist, (+/-)-2,5-dimethoxy-4-iodoamphetamine (DOI) onto the Vc/C2 region significantly reduced deep-nociceptive unit discharges evoked by formalin injection into the masseter muscle. Noxious pinch stimulation to the facial skin-evoked skin-WDR unit discharges was significantly reduced by topical administration of 0.1 mg/rat DOI onto the Vc/C2 region. Second, we tested whether i.c.v. administration of DOI affected Fos-like immunoreactivity (-LI) evoked by formalin injection into the masseter muscle. Fos-LI was significantly induced mainly at the ventrolateral (vl) area of trigeminal subnucleus interpolaris (Vi)/Vc junction (vl-Vi/Vc) region and Vc/C2 region in vehicle-treated rats. Formalin-evoked Fos-LI was significantly reduced in laminae I-II of the Vc/C2, but not vl-Vi/Vc region after i.c.v. administration of DOI. Finally, orofacial nocifensive behavioral activities evoked by formalin injection into the masseter muscle were significantly reduced by intracisternal administration of DOI. These results suggest that 5HT2A receptors in the Vc/C2 region mediate antinociceptive effects in the craniofacial nociception.
Okamoto
K
K
Department of Physiology, Wakayama Medical University, Kimiidera 811-1, Wakayama City, 641-8509, Japan. okamo007@umn.edu
Imbe
H
H
Kimura
A
A
Donishi
T
T
Tamai
Y
Y
Senba
E
E
D000200:Action Potentials / Q000187:drug effects; D000662:Amphetamines / Q000494:pharmacology; D000818:Animals; D001522:Behavior, Animal; D004195:Disease Models, Animal; D004347:Drug Interactions; D005157:Facial Pain / Q000378:metabolism* / Q000503:physiopathology*; D005557:Formaldehyde / Q000494:pharmacology; D007839:Functional Laterality; D007650:Ketanserin / Q000494:pharmacology; D008297:Male; D009474:Neurons / Q000187:drug effects / Q000502:physiology; D009619:Nociceptors / Q000503:physiopathology*; D016761:Oncogene Proteins v-fos / Q000378:metabolism; D010147:Pain Measurement / Q000187:drug effects / Q000379:methods; D010812:Physical Stimulation; D051381:Rats; D017207:Rats, Sprague-Dawley; D044402:Receptor, Serotonin, 5-HT2A / Q000502:physiology*; D012702:Serotonin Antagonists / Q000494:pharmacology; D017366:Serotonin Receptor Agonists / Q000494:pharmacology; D014279:Trigeminal Nucleus, Spinal / Q000473:pathology
D000662:Amphetamines; D016761:Oncogene Proteins v-fos; D044402:Receptor, Serotonin, 5-HT2A; D012702:Serotonin Antagonists; D017366:Serotonin Receptor Agonists; D005557:Formaldehyde; D007650:Ketanserin; C015952:4-iodo-2,5-dimethoxyphenylisopropylamine